title: MYOPIC CHOROIDAL NEOVASCULARIZATION: Diagnosis and Treatment.
abstract: OBJECTIVE
  To review and summarize the latest developments in the diagnosis and management of myopic choroidal neovascularization (mCNV).
  
  
  METHODS
  A review of the literature was performed, focusing on tests and investigations for diagnosing mCNV, as well as the key treatment options available for mCNV.
  
  
  RESULTS
  Standard essential tests and investigations for diagnosing mCNV include spectral-domain optical coherence tomography for screening, fluorescein angiography for confirmation, and indocyanine green angiography and fundus autofluorescence for providing supplementary information. The current first line treatment of mCNV is the use of anti-vascular endothelial growth factor therapy.
  
  
  CONCLUSIONS
  Various investigations can assist the differentiation of mCNV from other coexisting retinal pathologies associated with myopia or choroidal neovascularization resulting from other causes. Prompt use of anti-vascular endothelial growth factor therapy has good efficacy and safety in the treatment of mCNV.
authors.affiliation: *Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong; †2010 Retina & Macula Centre, Tsim Sha Tsui, Kowloon, Hong Kong; ‡Singapore National Eye Centre, Singapore; §Eye Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore; ¶Singapore Eye Research Institute, Singapore; and ‖Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
authors.forename: Timothy Y Y
authors.initials: TY
authors.lastname: Lai
authors.forename: Chui Ming Gemmy
authors.initials: CM
authors.lastname: Cheung
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy*; D004396:Coloring Agents / Q000008:administration & dosage; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green / Q000008:administration & dosage; D047728:Myopia, Degenerative / Q000175:diagnosis* / Q000188:drug therapy*; D061848:Optical Imaging; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D004396:Coloring Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D007208:Indocyanine Green